S – Subjective (Patient History)
* Patient reports experiencing hot flushes and irregular periods for the past 6 months.
* Menopausal status:
* ✓ Perimenopausal
* Symptoms reported:
* ✓ hot flushes
* ✓ irregular periods
* Impact on daily life and wellbeing:
* Reports sleep disturbance due to night sweats.
* Experiencing mood changes, including increased irritability.
Medical history:
* Chronic conditions:
* Nil reported.
* Surgical history:
* Appendectomy at age 12.
* Family history:
* Mother diagnosed with breast cancer at age 60.
Reproductive history:
* Age at menarche:
* 13 years old.
* Parity:
* G2P2.
* Contraceptive history:
* Used combined oral contraceptive pill for 10 years, ceased 2 years ago.
Medication history and allergies:
* Current medications:
* Nil.
* Allergies:
* No known allergies.
Contraindications to treatment:
* Nil reported.
O – Objective (Examination & Investigations)
Vital signs:
* Blood pressure in mmHg:
* 130/80 mmHg.
* Height in cm:
* 165 cm.
* Weight in kg:
* 70 kg.
* BMI:
* 25.8 kg/m².
Physical examination:
* General examination findings:
* Patient appears well.
* Gynaecological examination findings:
* Not performed.
Investigations initiated:
* ✓ Cervical screening (if due)
* ✓ Blood tests (FSH, Estradiol, TSH, Lipids, Vitamin D, others)
Referrals made:
* ✓ Gynaecologist
A – Assessment
"Menopause/perimenopause health assessment in accordance with MBS Item 695."
* Symptoms consistent with:
* ✓ Perimenopause
P – Plan
Management discussion:
Non-pharmacological options:
* ✓ lifestyle changes
* ✓ sleep strategies
Pharmacological options:
* ✓ MHT/HRT (benefits and risks discussed)
Patient-centred management plan:
* Symptom management agreed:
* Trial of low-dose HRT discussed and agreed upon.
* Follow-up arranged:
* Review in 3 months.
* "Discussed shared decision-making"
Preventative care advice:
* ✓ physical activity
* ✓ weight management
Eligibility check:
* ✓ No Item 695 claimed in last 12 months
* ✓ Patient meets criteria.
Billing:
MBS Item: "695 – Menopause/Perimenopause Assessment"
[Date of assessment]: 1 November 2024